The Myasthenia Gravis Treatment Global Market Report 2023, provides comprehensive information on the myasthenia gravis treatment market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Myasthenia Gravis Treatment Market’s Growth:
The global myasthenia gravis treatment market size is expected to grow from $1.31 billion in 2022 to $1.42 billion in 2023 at a compound annual growth rate (CAGR) of 8.46%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of market is expected to reach $1.90 billion in 2027 at a CAGR of 7.50%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
Product innovations are a key trend gaining popularity in the myasthenia gravis treatment market. Major companies operating in the myasthenia gravis treatment market are focused on developing new solutions to sustain their position in the market. For example, in December 2021, Argenx SE, a Netherlands-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug VYVGARTô (efgartigimod alfa-fcab) for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis. With this approval, VYVGART has become the first and only FDA-approved neonatal Fc receptor (FcRn) blocker used for generalized myasthenia gravis treatment. The company has reached agreements in principle with several regional and national commercial payers to structure a value-based agreement, providing appropriate access for patients and predictability of cost for payers.
The myasthenia gravis treatment market is segmented:
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses
North America was the largest region in the myasthenia gravis treatment market in 2022.
The table of contents in TBRC’s myasthenia gravis treatment market report includes:
- Executive Summary
- Myasthenia Gravis Treatment Market Characteristics
- Myasthenia Gravis Treatment Market Trends And Strategies
- Myasthenia Gravis Treatment Market – Macro Economic Scenario
- Myasthenia Gravis Treatment Market Segmentation
- Global Myasthenia Gravis Treatment Market Competitive Benchmarking
- Global Myasthenia Gravis Treatment Market Competitive Dashboard
- Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market
- Myasthenia Gravis Treatment Market Future Outlook and Potential Analysis
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model